TABLE 1.
Demographic and baseline characteristics of recovered COVID‐19 patients
| Participants (n = 39) | ||
|---|---|---|
| Patient characteristics | Age at recruitment (years); median (IQR) | 43 (32, 56) |
| Males; n (%) | 28 (71.8) | |
| Ethnicity; n (%) | ||
| Chinese | 12 (30.8) | |
| Malay | 2 (5.1) | |
| Indian | 17 (20.5) | |
| Others | 8 (20.5) | |
| Months from infection to first blood sampling; mean (SD) | 12.7 (3.6) | |
| COVID‐19 vaccinated a | 29 (74.4) | |
| BMI (kg/m2); median (IQR) | 26.3 (22.3, 30.2) | |
| Waist circumference (cm); median (IQR) | 91.5 (82, 99) | |
| Average systolic blood pressure (mmHg); median (IQR) | 121 (114, 139) | |
| Average diastolic blood pressure (mmHg); median (IQR) | 72 (66, 82) | |
| Patient comorbidities | Diabetes mellitus; n (%) | 11 (28.2) |
| Hypertension; n (%) | 7 (18.0) | |
| Hyperlipidemia; n (%) | 10 (25.6) | |
| Previous cardiac AMI; n (%) | 3 (7.7) | |
| Previous Stroke; n (%) | 0 (0.0) | |
| Previous deep vein thrombosis; n (%) | 0 (0.0) | |
| COVID‐19 severity | Asymptomatic COVID‐19 | 11 (30.8) |
| Mild to moderate COVID‐19 | 19 (48.7) | |
| Severe COVID‐19 (PaO2/FiO2 < 300 mmHg) | 2 (5.1) | |
| Critical COVID‐19 (requiring intensive care) | 7 (17.9) | |
| Treatment | Thromboprophylaxis | 5 (12.8) |
| Remdesivir | 9 (23.1) | |
| Tocilizumab | 3 (7.7) | |
| Dexamethasone | 3 (7.7) | |
| Lopinavir/ritonavir | 3 (7.7) | |
| Thrombotic complications | COVID‐19 associated thrombosis; n (%) | 2 (5.1) |
| Post Covid‐19 thrombosis; n (%) | 1 (2.6) | |
| Laboratory parameters | Fasting glucose; median (IQR) | 5.5 (5.0, 6.0) |
| HbA1c (%); median (IQR) | 5.5 (5.3, 6.2) | |
| Total cholesterol; median (IQR) | 4.9 (4.1, 5.5) | |
| HDL; median (IQR) | 1.3 (1.1, 1.4) | |
| LDL; mean (SD) | 3.0 (1.0) | |
| C‐reactive protein (mg/L); median (IQR) b | 3.7 (0.9, 20.4) | |
| Hemoglobin (g/dL); median (IQR) | 14.5 (12.8, 15.2) | |
| White Blood Cells (109/L); median (IQR) | 6.2 (5.2, 7.0) | |
| Platelets; median (IQR) | 228 (194, 273) | |
a
Received primary COVID‐19 mRNA vaccination (second dose only). No adverse event observed.
b
Insufficient plasma sample in one patient, hence C‐reactive protein levels not performed.